GlassScriptPhysician profile
Edith L Saffo
NPI 1235296013
$19,022.46
in general payments reported to CMS, 2019-2025
30 companies · $6,693 in 2025
The $6,693 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,875 · 2022: $2,724 · 2023: $4,264 · 2024: $3,466 · 2025: $6,693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $2,879 · Education: $319 · Travel and Lodging: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,929.70 |
| Consulting Fee | $2,879.00 |
| Education | $318.98 |
| Travel and Lodging | $295.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,817.73 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $2,843.92 | 2021-2025 | Ilumya, Blu-U, Winlevi |
| Ucb, INC. | $2,234.91 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $1,870.86 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $1,368.57 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,051.33 | 2021-2025 | Dupixent |
| Leo Pharma INC. | $979.74 | 2021-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $958.89 | 2021-2025 | Tremfya |
| Pfizer INC. | $717.45 | 2021-2025 | |
| Genzyme Corporation | $480.42 | 2021-2025 | |
| Lilly USA, LLC | $392.72 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $318.73 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $226.35 | 2021-2025 | Nemluvio, Epsolay |
| Incyte Corporation | $224.61 | 2021-2024 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $218.85 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $212.52 | 2023-2024 | Vtama |
| Organon LLC | $209.65 | 2025 | Vtama |
| Almirall LLC | $199.17 | 2022-2023 | Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.50 | 2023-2025 | Spevigo, Cyltezo |
| Epi Health, LLC | $105.56 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $91.67 | 2021 | |
| Janssen Scientific Affairs, LLC | $87.36 | 2024 | Tremfya |
| Verrica Pharmaceuticals INC. | $57.33 | 2023-2025 | Ycanth |
| Sandoz INC. | $54.66 | 2023-2024 | Hyrimoz |
| Biofrontera INC. | $43.42 | 2022-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Biocryst US Sales Co., LLC | $18.97 | 2022 | |
| Amgen INC. | $18.82 | 2023 | Otezla |
| Journey Medical Corporation | $17.75 | 2022 | |
| Genentech USA, INC. | $17.62 | 2023 | Erivedge |
| Sebela Pharmaceuticals INC. | $12.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edith Saffo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.